vs
Enact Holdings, Inc.（ACT）与ANI PHARMACEUTICALS INC（ANIP）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.3倍（$312.7M vs $247.1M），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 3.6%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
ACT vs ANIP — 直观对比
营收规模更大
ACT
是对方的1.3倍
$247.1M
营收增速更快
ANIP
高出26.0%
3.6%
两年增速更快
ANIP
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $247.1M |
| 净利润 | — | $27.5M |
| 毛利率 | — | — |
| 营业利润率 | 71.3% | 14.1% |
| 净利率 | — | 11.1% |
| 营收同比 | 3.6% | 29.6% |
| 净利润同比 | — | 367.5% |
| 每股收益（稀释后） | $1.23 | $1.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTANIP
| Q4 25 | $312.7M | $247.1M | ||
| Q3 25 | $311.5M | $227.8M | ||
| Q2 25 | $304.9M | $211.4M | ||
| Q1 25 | $306.8M | $197.1M | ||
| Q4 24 | $301.8M | $190.6M | ||
| Q3 24 | $309.6M | $148.3M | ||
| Q2 24 | $298.8M | $138.0M | ||
| Q1 24 | $291.6M | $137.4M |
净利润ACTANIP
| Q4 25 | — | $27.5M | ||
| Q3 25 | — | $26.6M | ||
| Q2 25 | — | $8.5M | ||
| Q1 25 | — | $15.7M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | — | $-24.2M | ||
| Q2 24 | — | $-2.3M | ||
| Q1 24 | — | $18.2M |
营业利润率ACTANIP
| Q4 25 | 71.3% | 14.1% | ||
| Q3 25 | 67.4% | 15.9% | ||
| Q2 25 | 70.4% | 6.6% | ||
| Q1 25 | 68.9% | 13.3% | ||
| Q4 24 | 68.9% | -2.3% | ||
| Q3 24 | 74.1% | -13.8% | ||
| Q2 24 | 78.6% | 3.7% | ||
| Q1 24 | 70.6% | 14.8% |
净利率ACTANIP
| Q4 25 | — | 11.1% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 8.0% | ||
| Q4 24 | — | -5.4% | ||
| Q3 24 | — | -16.3% | ||
| Q2 24 | — | -1.7% | ||
| Q1 24 | — | 13.2% |
每股收益（稀释后）ACTANIP
| Q4 25 | $1.23 | $1.14 | ||
| Q3 25 | $1.10 | $1.13 | ||
| Q2 25 | $1.11 | $0.36 | ||
| Q1 25 | $1.08 | $0.69 | ||
| Q4 24 | $1.05 | $-0.45 | ||
| Q3 24 | $1.15 | $-1.27 | ||
| Q2 24 | $1.16 | $-0.14 | ||
| Q1 24 | $1.01 | $0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $285.6M |
| 总债务越低越好 | $744.5M | — |
| 股东权益账面价值 | $5.4B | $540.7M |
| 总资产 | $6.9B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTANIP
| Q4 25 | $582.5M | $285.6M | ||
| Q3 25 | $545.6M | $262.6M | ||
| Q2 25 | $616.0M | $217.8M | ||
| Q1 25 | $639.0M | $149.8M | ||
| Q4 24 | $602.8M | $144.9M | ||
| Q3 24 | $674.9M | $145.0M | ||
| Q2 24 | $711.3M | $240.1M | ||
| Q1 24 | $624.3M | $228.6M |
总债务ACTANIP
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | — |
股东权益ACTANIP
| Q4 25 | $5.4B | $540.7M | ||
| Q3 25 | $5.3B | $505.8M | ||
| Q2 25 | $5.2B | $436.8M | ||
| Q1 25 | $5.1B | $418.6M | ||
| Q4 24 | $5.0B | $403.7M | ||
| Q3 24 | $5.0B | $405.9M | ||
| Q2 24 | $4.8B | $455.8M | ||
| Q1 24 | $4.7B | $452.0M |
总资产ACTANIP
| Q4 25 | $6.9B | $1.4B | ||
| Q3 25 | $6.9B | $1.4B | ||
| Q2 25 | $6.8B | $1.3B | ||
| Q1 25 | $6.7B | $1.3B | ||
| Q4 24 | $6.5B | $1.3B | ||
| Q3 24 | $6.6B | $1.3B | ||
| Q2 24 | $6.3B | $920.8M | ||
| Q1 24 | $6.3B | $914.5M |
负债/权益比ACTANIP
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $30.4M |
| 自由现金流经营现金流 - 资本支出 | — | $29.1M |
| 自由现金流率自由现金流/营收 | — | 11.8% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | — | $171.4M |
8季度趋势，按日历期对齐
经营现金流ACTANIP
| Q4 25 | $724.5M | $30.4M | ||
| Q3 25 | $192.0M | $44.1M | ||
| Q2 25 | $119.5M | $75.8M | ||
| Q1 25 | $226.7M | $35.0M | ||
| Q4 24 | $686.3M | $15.9M | ||
| Q3 24 | $188.1M | $12.5M | ||
| Q2 24 | $144.7M | $17.4M | ||
| Q1 24 | $187.3M | $18.3M |
自由现金流ACTANIP
| Q4 25 | — | $29.1M | ||
| Q3 25 | — | $38.0M | ||
| Q2 25 | — | $71.8M | ||
| Q1 25 | — | $32.5M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | — | $13.0M | ||
| Q1 24 | — | $13.7M |
自由现金流率ACTANIP
| Q4 25 | — | 11.8% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 34.0% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 9.4% | ||
| Q1 24 | — | 10.0% |
资本支出强度ACTANIP
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 3.3% |
现金转化率ACTANIP
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 8.87× | ||
| Q1 25 | — | 2.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
